Seattle Genetics’ Achievements in Drug Development

Seattle Genetics is a research company that has made significant achievements in search for cancer treatment thanks to Clay Siegall. It has focused on helping cancer patients through the provision of research drugs that are effective in treating cancer. It also develops antibody-drug conjugates (ADCs) that are used to treat different kinds of lymphomas. Recently, the company’s CEO announced their plan to introduce more drugs into the market. He also announced the company’s intention to hire 100 more employees. The hiring plan aims at adding 100 employees into their U.S. firm and 20 more in their Switzerland office. It will increase their operations as a research center.

Novel cancer treatment drugs
According to Siegall, Seattle Genetics has a drug known as Adcetris that is currently undergoing clinical trials. The drug is currently being tested against different lymphomas in 70 trials. In the trial, it is being used to treat new or untreated Hodgkin lymphoma. Last year, the drug bagged $226million in sales in Canada and the U.S. In 2016, the sale of Adcetris is expected to range between $255 million and $275 million. Takeda Pharmaceutical is dedicated to selling the drug in other areas beyond U.S. and Canada.

Apart from Adcetris, Seattle Genetics is currently developing 12 new drugs. 33A is a drug that is set for phase three clinical trial. It is being tested for treatment of acute myeloid leukemia. The company is also doing advanced research on two drugs that treat bladder cancer, as well as a drug for breast cancer.

About Dr. Clay
Dr. Clay B. Siegall is a scientist, a co-founder of Seattle Genetics. He founded this research firm in 1998, and he is the company’s Chief Executive Officer, President, and the board’s chairman. Dr. Clay holds a bachelor’s degree in Zoology and a doctorate in Genetics from Washington University. He is a great science author with more than 70 publications.

Dr. Siegall has a rich career background in biotechnology. He worked for Bristol-Meyer Squibb pharmaceutical research institute from 1991 to 1997. He later moved to National Cancer Institute. For 17 years he worked for National Institute of Health. Alda Pharmaceuticals and Mirna Therapeutics are the two largest companies that Dr. Siegall has served as a board member.